Soliris Approved to Treat Neuromyelitis Optica Spectrum Disorder

FRIDAY, June 28, 2019 -- The U.S. Food and Drug Administration has approved Soliris (eculizumab) injection as the first treatment for neuromyelitis optica spectrum disorder (NMOSD), the agency announced Thursday. Soliris is indicated for intravenous...

https://www.drugs.com/news/soliris-approved-neuromyelitis-optica-spectrum-disord...

Source: Drugs.com - Pharma News - June 28, 2019 Category: Pharmaceuticals Source Type: news

More News: Brain | Food and Drug Administration (FDA) | Neurology | Pharmaceuticals